The trial focuses on women who need labour induction, a process used when a pregnancy has reached term but labor has not started on its own. The medication being tested is a low‑dose oral tablet called Angusta 25 µg, which contains the active ingredient misoprostol. In addition, small devices known as osmotic dilators are used; they gently expand the cervix by absorbing fluid, helping it become ready for labor.
The purpose of the study is to determine whether giving the tablet and the dilators at the same time reduces the total amount of misoprostol needed compared with giving them one after the other. Women will be randomly assigned to either a concurrent group, where both treatments start together, or a sequential group, where the dilators are placed first and the tablet is added later. The trial is open‑label, meaning both the participants and the health‑care team know which schedule is being used.
During the study, participants will be monitored for the number of tablet doses required, any side effects such as strong uterine contractions (called uterine tachysystole) or infection, and the progress of labor, including how often a vaginal delivery is achieved and whether any surgical delivery is needed. Information about the newborn’s health, such as birth weight and early breathing score, will also be recorded. The study follows the participants from the start of induction until discharge from the hospital after birth.
Czechia 
